Altimmune, Inc. (NASDAQ: ALT) reported Q4 EPS of ($0.54), $0.10 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $37 thousand versus the consensus estimate of $2.14 thousand.

For earnings history and earnings-related data on Altimmune, Inc. (ALT) click here.